Delaware
(State
or Other Jurisdiction of
Incorporation)
|
000-30929
(Commission
File Number)
|
13-4087132
(IRS
Employer Identification No.)
|
£ |
Written
communications pursuant to Rule 425 under the Securities
Act.
|
£ |
Soliciting
material pursuant to Rule 14a-12 under the Exchange
Act.
|
£ |
Pre-commencement
communications pursuant to Rule 14d-2b under the Exchange
Act.
|
£ |
Pre-commencement
communications pursuant to Rule 13e-4(c) under the Exchange
Act.
|
Item 5.02. |
Departure
of Directors or Certain Officers; Election of Directors;
Appointment
of Certain Officers; Compensatory Arrangements of Certain
Officers.
|
(b) |
On
June 18, 2007, Keryx Biopharmaceuticals, Inc. (“Keryx”) announced the
resignation of Ronald C. Renaud, Jr., effective June 27, 2007, as
the
Company’s Senior Vice President and Chief Financial Officer for personal
and family reasons. The text of a press release announcing the resignation
of Mr. Renaud is attached as Exhibit 99.1 and is incorporated by
reference
into this Item 5.02.
|
(c) |
On
June 18, 2007, Keryx announced that Mark Stier, age 47, will assume
responsibilities
for all financial functions at Keryx.
|
Item 9.01. |
Financial
Statements and Exhibits.
|
(d) |
Exhibits
|
Exhibit
|
|
Number
|
Description
|
99.1
|
Press
Release dated June 18, 2007.
|
Keryx
Biopharmaceuticals, Inc.
(Registrant)
|
||
Date: June 18, 2007 | ||
|
|
|
By: | /s/ Beth F. Levine | |
Beth
F. Levine
|
||
Senior
Vice President and General
Counsel
|
Exhibit
|
|
Number
|
Description
|
99.1
|
Press
Release dated June 18, 2007.
|